Clearmind's CMND-100 Shows Continued Safety in Phase I/IIa Trial for Alcohol Use Disorder
Event summary
- Clearmind Medicine reported additional positive safety results from the second cohort of its Phase I/IIa trial for CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).
- The trial, conducted across Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, showed no serious adverse events and strong tolerability.
- The Data and Safety Monitoring Board (DSMB) unanimously approved advancing to the second cohort following favorable results from the first cohort.
The big picture
Clearmind's positive safety results for CMND-100 reinforce its potential as a novel therapeutic for Alcohol Use Disorder, an area with significant unmet medical needs. The continued validation of its non-hallucinogenic profile positions the company favorably in the growing psychedelic therapeutics market, where safety and tolerability are critical for regulatory approval and commercial success.
What we're watching
- Clinical Progression
- How the continued positive safety data will impact the timeline for advancing CMND-100 to later-stage clinical trials.
- Regulatory Pathway
- Whether the favorable safety profile will facilitate smoother regulatory approval processes for CMND-100.
- Market Differentiation
- The pace at which Clearmind can establish CMND-100 as a leading non-hallucinogenic treatment option for AUD in a competitive landscape.
Related topics